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Ask the expert* 
What treatment would you advise for a 1-year-old child 
with chronic renal failure who has been on aluminum 
hydroxide as a phosphate binder for 6 months and then 
develops epilepsy and is found to have a grossly raised 
plasma aluminum concentration? 
Key word: Aluminium encephalopathy 
The immediate approach advises discontinuation of aluminum hydroxide 
as a phosphate-binding agent and other pharmacological agents contain- 
ing aluminum (A1), such as Sicralfate or Kaopectate. On a statistical 
basis, this young child is likely to have obstructive uropathy with renal 
dysplasia and renal bicarbonate wasting, and probably should be treated 
with Shol's solution. The most likely diagnosis in this child is that 
gastrointestinal absorption of A1 has resulted in encephalopathy and 
probably, as well in microcytic anemia and vitamin D-resistant 
osteomalacia [1]. Severe A1 intoxication may develop when Al-contain- 
ing binders and buffered citrate solutions are ingested together, since 
citrate markedly enhances the intestinal absorption [2]. 
In some children who have sufficient residual renal function that 
permits A1 excretion, intoxication can resolve after administration of 
Al-containing binders is stopped. As described, this child already has 
convulsions, which presumably are not due to uremia or another meta- 
bolic disorder, but rather to Al-induced encephalopathy. Thus, therapy 
with deferoxamine (DFO) is indicated. 
DFO is effective in treating A1 intoxication in non-dialyzed patients 
with chronic renal failure (CRF) and in patients undergoing all forms of 
dialysis. Because A1 is tightly bound to proteins, essentially none is 
removed by dialysis in the absence of a chelating agent such as DFO. 
DFO forms a freely diffusable chelate which can be given by the in- 
travenous, intramuscular, or intraperitoneal route. Long-term therapy 
with DFO should be reserved for those patients with well-documented 
evidence of A1 toxicity, including bone disease and neurological involve- 
ment [3, 4]. DFO can cause lens abnormalities, leukopenia, cardiac 
arrhythmias and allergic reactions. It recently has been associated with 
fatal infections involving Yersinia and Rhizopus (a fungus, [5]). Thus, 
DFO should be administered cautiously at a dosage of 10-20 mg/kg 
once a week; plasma A1 levels should be monitored after DFO therapy is 
begun. Plasma A1 levels should not exceed 800-1000 pg/1, because 
greater values may exacerbate the encephalopathy. The duration of DFO 
therapy is difficult to estimate. However, because of its toxicity, DFO 
should be discontinued as soon as maximal clinical improvement is 
noted. 
* The editors invite questions for this section 
Al-induced encephalopathy, osteomalacia and microcytic anemia 
are iatrogenic diseases; hence, they are preventable. Because the main 
cause of A1 intoxication in a child with CRF is the gastrointestinal 
absorption of A1, Al-containing antacids should not be given. Infant diet 
can be regulated adequately by using a low phosphate formula with the 
addition of calcium carbonate as needed [6]. If small amounts of Al are 
needed to control serum phosphate concentrations, calcium citrate should 
be avoided as this enhances the intestinal absorption of AI. 
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